Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy

European Journal of Cancer

Volumn 40, Issue 2, 2004, Pages 205-211

  Petit, T ^a   Wilt, M ^a   Velten, M ^a   Millon, R ^a   Rodier, J F ^a   Borel, C ^a   Mors, R ^a   Haegele P ^a   Eber, M ^a   Ghnassia, J P ^a  

^a CENTRE PAUL STRAUSS   (France)

Author keywords

Breast cancer; Neoadjuvant chemotherapy; Predictive factors

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CELL SURFACE RECEPTOR; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE II ALPHA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FEC PROTOCOL; FLUOROURACIL; HORMONE; KI 67 ANTIGEN; TAMOXIFEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BREAST CARCINOMA; BREAST TUMOR; CANCER GRADING; CELL PROLIFERATION; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; MEDICAL ASSESSMENT; METABOLISM; METHODOLOGY; MULTIVARIATE ANALYSIS; PATHOLOGY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 9144242764     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(03)00675-0     Document Type: Article

References (38)

1. Pierga J.Y., Mouret E., Laurence V., et al. Prognostic factors for survival after neoadjuvant chemotherapy in operable breast cancer. The role of clinical response. Eur. J. Cancer. 39:2003;1089-1096.
2. Chollet P., Amat S., Cure H., et al. Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer. Br. J. Cancer. 86:2002;1041-1046.
3. Piccart M.J., Di Leo A., Hamilton A. HER2. a predictive factor ready to use in the daily management of breast cancer patients? Eur. J. Cancer. 36:2000;1755-1761.
4. Yamauchi H., Stearns V., Hayes D.F. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J. Clin. Oncol. 19:2001;2334-2356.
5. Liu L.F. DNA topoisomerase poisons as anti-tumor drugs. Ann. Rev. Biochem. 58:1989;351-375.
6. Jarvinen T.A., Tanner M., Rantanen V., et al. Amplification and deletion of topoisomerase ha associate with HER-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am. J. Pathol. 156:2000;839-847.
7. Chevallier B., Roche H., Olivier J.P., Chollet P., Hurteloup P. Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am. J. Clin. Oncol. 16:1993;223-228.
8. Sataloff D.M., Mason B.A., Prestipino A.J., Seinige U.L., Lieber C.P., Baloch Z. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast. a determinant of outcome J. Am. Coll. Surg. 180:1995;297-306.
9. Gerdes J., Lemke H., Baisch H., Wacker H.H., Schwab U., Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J. Immunol. 133:1984;1710.
10. Elston C.W., Ellis J.O. Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer. experience from a large study with long-term follow-up Histopathology. 19:1991;403-410.
11. Di Leo A., Larsimont D., Gancberg D., et al. HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide. Ann. Oncol. 12:2001;1081-1089.
12. Fleiss J.L. Statistical Methods for Rates and Proportions. 1981;John Wiley & Sons, New York.
13. Herrada J., Iyer R.B., Atkinson E.N., Sneige N., Buzdar A.U., Hortobagyi O.N. Relative value of physical examination, mammography, and breast sonography in evaluating the size of the primary tumor and regional lymph node metastases in women receiving neoadjuvant chemotherapy for locally advanced breast carcinoma. Clin. Cancer Res. 3:1997;1565-1569.
14. Lluch A., Cervantes A., Pardo J.D., et al. Assessment of primary tumor and axillary involvement in breast cancer after neoadjuvant chemotherapy. A comparison of clinical examination, mammography, ultrasonography and CT-scan. Proc. Am. Soc. Clin. Oncol. 14:1995;135. (abstr).
15. Amat S., Penault-Llorca F., Cure H., et al. Scarf-Bloom-Richardson (SBR) grading. a pleiotropic marker of chemosensitivity in invasive ductal breast carcinomas treated by neoadjuvant chemotherapy Int. J. Oncol. 20:2002;791-796.
16. Aas T., Geisler S., Eide G.E., et al. Predictive value of tumour cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy. Eur. J. Cancer. 39:2003;438-446.
17. MacGrogan G., Mauriac L., Durand M., et al. Primary chemotherapy in breast invasive carcinoma. predictive value of the immunohistochemical detection of hormonal receptors, p53, c-HER-2, MiB1, p52, and GSTπ Br. J. Cancer. 74:1996;1458-1465.
18. Daidone M.G., Veneroni S., Benini E., et al. Biological markers as indicators of response to primary and adjuvant chemotherapy in breast cancer. Int. J. Cancer. 84:1999;580-586.
19. Remvikos Y., Jouve M., Beuzeboc P., Viehl P., Magdelenat H., Pouillart P. Cell cycle modifications of breast cancers during neoadjuvant chemotherapy. a flow cytometry study on fine needle aspirates Eur. J. Cancer. 29A:1993;1843-1848.
20. Colleoni M., Orvieto E., Nole F., et al. Prediction of response to primary chemotherapy for operable breast cancer. Eur. J. Cancer. 35:1999;574-579.
21. Couturier J., Vincent-Salomon A., Nicolas A., et al. Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of HER-2 gene status in breast cancer. Mod. Pathol. 13:2000;1238-1243.
22. Pauletti O., Dandekar S., Rong H., et al. Assessment of methods tissue-based detection of HER-2/neu alteration in breast cancer. a direct comparison of fluorescence in situ hybridization and immunochemistry J. Clin. Oncol. 18:2000;3651-3664.
23. O'Malley F.P., Parkes R., Latta E., et al. Comparison of HER2/neu status assessed by quantitative polymerase chain reaction and inununochemistry. Am. J. Clin. Path. 115:2001;504-511.
24. Keliner U., Rudolph P., Parwaresch R. Human DNA-topoisomerase. diagnostic and therapeutic implications for cancer Onkologie. 23:2000;424-430.
25. Lynch B.J., Guinee D.G. Jr., Holden J.A. Human DNA topoisomerase II alpha. a new marker of cell proliferation in invasive breast cancer Hum. Pathol. 28:1997;1180-1188.
26. Thor A.D., Berry D.A., Budman D.R., et al. ErbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J. Natl. Cancer Inst. 90:1998;1346-1360.
27. Paik S., Bryant J., Park C., et al. ErbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J. Natl. Cancer Inst. 90:1998;1320-1327.
28. Ravdin P.M., Green S., Albain K.S., et al. Initial report of the SWOG biological correlative study of c-erbB-2 expression as a predictor of outcome in a trial comparing adjuvant CAF T with tamoxifen alone. Proc. Am. Soc. Clin. Oncol. 17:1998;97a. (abstr).
29. Vargas-Roig L.M., Gago F.E., Tello O., Martin de Civetta M.T., Ciocca D.R. ErbB-2 protein and drug resistance in breast cancer patients treated with induction chemotherapy. Int. J. Cancer. 84:1999;129-134.
30. Vincent-Salomon A., Carton M., Freneaux P., et al. ErbB-2 overexpression in breast carcinomas. no positive correlation with complete pathological response to preoperative high-dose anthracycline-based chemotherapy Eur. J. Cancer. 36:2000;586-591.
31. Zhang F., Yang Y., Smith I., et al. Correlation between HER2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma. Cancer. 97:2003;1758-1765.
32. Faneyte I.F., Schrama J.O., Peterse J.L., Remijnse P.L., Rodenhuis S., Van de Vijver M.J. Breast cancer response to neoadjuvant chemotherapy. predictive markers and relation with outcome Br. J. Cancer. 88:2003;406-412.
33. Willsher P.C., Pinder S.E., Gee J.M., et al. C-erbB-2 expression predicts response to preoperative chemotherapy for locally advanced breast cancer. Anticancer Res. 18:1998;3695-3698.
34. Geisler S., Lonning P.E., Aas T., et al. Influence of p53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res. 61:2001;2505-2512.
35. Petit T., Borel C., Ghnassia J.P., et al. Chemotherapy response of breast cancer depends on HER-2 status and anthracycline dose intensity in the neoadjuvant setting. Clin. Cancer Res. 7:2001;1577-1581.
36. Coon J.S., Marcus E., Gupta-Burt S., et al. Amplification and overexpression of topoisomerase Ha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin. Cancer Res. 8:2002;1061-1067.
37. Park K., Kim J., Lim S., Han S. Topoisomerase IIα and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy. Eur. J. Cancer. 39:2003;631-634.
38. Van't Veer L.J., Dai H., van de Vijver M.J., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 415:2002;530-536.